Clinical Trial Update: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy plus cetuximab with VTX-2337 in recurrent/metastatic squamous cell carcinoma of the head and neck has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• VTX-2337 (TLR8 agonist)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2019-10-29